Skip to main content
Erschienen in: hautnah dermatologie 5/2018

14.09.2018 | Systemischer Lupus erythematodes | Fortbildung

Chronisch-entzündliche Hauterkrankung

Kutaner Lupus erythematodes: eine Krankheit, viele Ausprägungsformen

Erschienen in: hautnah dermatologie | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Zusammenfassung

Aufgrund seiner vielen verschiedenen Ausprägungsformen ist der Lupus erythematodes nicht immer leicht zu diagnostizieren. Doch auch bei der Therapie der chronisch-entzündlichen Hauterkrankung gibt es Hürden und Risiken.
Literatur
1.
Zurück zum Zitat Gilliam JN. The cutaneous signs of lupus erythematosus. Cont Educ Fam Phys 1977; 6: 34–70 Gilliam JN. The cutaneous signs of lupus erythematosus. Cont Educ Fam Phys 1977; 6: 34–70
2.
Zurück zum Zitat Millard TP. Molecular Genetic of Cutaneous Lupus Erythematosus. In: Kuhn et al. Cutaneous Lupus Erythematosus. Berlin, Springer-Verlag, 2004: 205–11 Millard TP. Molecular Genetic of Cutaneous Lupus Erythematosus. In: Kuhn et al. Cutaneous Lupus Erythematosus. Berlin, Springer-Verlag, 2004: 205–11
3.
Zurück zum Zitat Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 2005; 4: 253–63CrossRefPubMed Sontheimer RD. Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological, and genetic findings. Autoimmun Rev 2005; 4: 253–63CrossRefPubMed
4.
Zurück zum Zitat Kuhn A et al. Lupus erythematosus tumidus — a neglected subset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol 2000;136:1033–41CrossRefPubMed Kuhn A et al. Lupus erythematosus tumidus — a neglected subset of cutaneous Lupus erythematosus: report of 40 cases. Arch Dermatol 2000;136:1033–41CrossRefPubMed
5.
Zurück zum Zitat Tebbe B et al. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 1997; 6: 96–104CrossRefPubMed Tebbe B et al. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 1997; 6: 96–104CrossRefPubMed
6.
Zurück zum Zitat Kuhn A et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 2001; 45: 86–95CrossRefPubMed Kuhn A et al. Phototesting in lupus erythematosus: a 15-year experience. J Am Acad Dermatol 2001; 45: 86–95CrossRefPubMed
7.
Zurück zum Zitat Boeckler P et al. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency. Br J Dermatol 2005; 152: 265–70CrossRefPubMed Boeckler P et al. The combination of complement deficiency and cigarette smoking as risk factor for cutaneous lupus erythematosus in men; a focus on combined C2/C4 deficiency. Br J Dermatol 2005; 152: 265–70CrossRefPubMed
8.
Zurück zum Zitat Artuz F et al. Efficacy of sulfasalazine in discoid lupus erythematosus. Int J Dermatol 1996; 35: 746–8CrossRefPubMed Artuz F et al. Efficacy of sulfasalazine in discoid lupus erythematosus. Int J Dermatol 1996; 35: 746–8CrossRefPubMed
9.
Zurück zum Zitat Yoshimasu T et al. Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). Eur J Dermatol 2001; 11: 54–7PubMed Yoshimasu T et al. Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). Eur J Dermatol 2001; 11: 54–7PubMed
10.
Zurück zum Zitat Kuhn A et al. Kutaner LE. 2013; AWMF Nr. 013/060 Kuhn A et al. Kutaner LE. 2013; AWMF Nr. 013/060
11.
Zurück zum Zitat Meier CR et al. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol 1998; 25: 1515–9PubMed Meier CR et al. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol 1998; 25: 1515–9PubMed
12.
Zurück zum Zitat Hampton PJ et al. Implication for photosensitive patients of ultraviolet A exposure in vehicles. Br J Dermatol 2004; 151: 873–6CrossRefPubMed Hampton PJ et al. Implication for photosensitive patients of ultraviolet A exposure in vehicles. Br J Dermatol 2004; 151: 873–6CrossRefPubMed
13.
Zurück zum Zitat Johnson JA et al. Broad-spectrum photoprotection: the roles of tinted auto windows, sunscreens and browning agents in the diagnosis and treatment of photosensitivity. Dermatology 1992; 185: 237–41CrossRefPubMed Johnson JA et al. Broad-spectrum photoprotection: the roles of tinted auto windows, sunscreens and browning agents in the diagnosis and treatment of photosensitivity. Dermatology 1992; 185: 237–41CrossRefPubMed
14.
Zurück zum Zitat Tzung TY et al. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol 2007; 156: 191–2CrossRefPubMed Tzung TY et al. Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study. Br J Dermatol 2007; 156: 191–2CrossRefPubMed
15.
Zurück zum Zitat Ochsendorf FR et al. Chloroquine retinopathy: avoidable by individualized daily dosing. Dtsch Med Wochenschr 1993; 118: 1895–8CrossRefPubMed Ochsendorf FR et al. Chloroquine retinopathy: avoidable by individualized daily dosing. Dtsch Med Wochenschr 1993; 118: 1895–8CrossRefPubMed
16.
Zurück zum Zitat Pelle MT et al. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002; 138: 1231–3PubMed Pelle MT et al. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002; 138: 1231–3PubMed
17.
Zurück zum Zitat Pisoni CN et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047–52PubMed Pisoni CN et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047–52PubMed
18.
Zurück zum Zitat Wallace DJ et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018; 392: 222–31CrossRefPubMed Wallace DJ et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018; 392: 222–31CrossRefPubMed
19.
Zurück zum Zitat Heine G, Lahl A, Müller C, Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. Br J Dermatol 2010; 163: 863–5CrossRefPubMed Heine G, Lahl A, Müller C, Worm M. Vitamin D deficiency in patients with cutaneous lupus erythematosus is prevalent throughout the year. Br J Dermatol 2010; 163: 863–5CrossRefPubMed
Metadaten
Titel
Chronisch-entzündliche Hauterkrankung
Kutaner Lupus erythematodes: eine Krankheit, viele Ausprägungsformen
Publikationsdatum
14.09.2018
Erschienen in
hautnah dermatologie / Ausgabe 5/2018
Print ISSN: 0938-0221
Elektronische ISSN: 2196-6451
DOI
https://doi.org/10.1007/s15012-018-2847-x

Weitere Artikel der Ausgabe 5/2018

hautnah dermatologie 5/2018 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.